Be Clinical, an Indian skincare startup focused on evidence-led formulations, has raised ₹6 crore in a seed round led by V3 Ventures, with participation from Titan Capital. The capital arrives as consumer demand rises for clinically validated, ingredient-forward skincare across India’s expanding beauty and personal care market.
Science-first approach to anti-ageing
Founded in May 2025 by Hemangi Dhir, Be Clinical positions itself as a science-first brand concentrated on anti-ageing solutions. The company emphasises in‑vivo testing, clinical validation and dermatologist-driven formulations rather than marketing-led claims.
Its portfolio covers face, body and scalp care, employing active ingredients at measured doses and validated through testing intended to deliver visible results. By prioritising research and efficacy, Be Clinical aims to address consumer scepticism around performance claims and build long-term trust.
Planned use of funds
The startup says the ₹6 crore will primarily strengthen research and development. Investments will expand the in‑house formulation team and broaden clinical testing across current and pipeline products to substantiate efficacy and safety claims.
Part of the funding will upgrade manufacturing infrastructure, including new machinery to boost production efficiency and maintain consistent quality at scale. The company also plans packaging improvements to better preserve ingredient stability and reinforce its clinical positioning.
Early traction and market opportunity
Though recently launched, Be Clinical reports having served more than 25,000 customers, reflecting growing acceptance of clinically driven skincare among Indian consumers. This aligns with a wider shift in purchasing behaviour: shoppers increasingly research ingredients, formulations and safety before buying.
India’s skincare market has long been dominated by mass‑market and global brands that may not be tailored to local skin types or climatic conditions. Be Clinical aims to bridge that gap by developing products tailored to Indian needs while adhering to global clinical standards.
Competitive positioning and outlook
The brand competes with legacy global players and rapidly scaling domestic direct‑to‑consumer firms. Its stated differentiation is measurable outcomes and clinical evidence rather than purely cosmetic promises—an approach designed to appeal to premium, results‑oriented consumers.
The seed round led by V3 Ventures signals investor confidence in science-backed consumer brands in India. With fresh capital, Be Clinical is positioned to accelerate product innovation, enhance operational capabilities and deepen engagement with consumers who prioritise evidence-based skincare.
